Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 2
1993 1
1994 3
1995 2
1996 3
1997 2
1998 2
1999 2
2000 3
2001 4
2002 1
2003 3
2004 4
2005 2
2006 5
2007 3
2008 3
2009 4
2010 5
2011 6
2012 12
2013 9
2014 19
2015 16
2016 14
2017 16
2018 15
2019 11
2020 13
2021 15
2022 20
2023 19
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Predictive biomarkers in gastric cancer.
Röcken C. Röcken C. J Cancer Res Clin Oncol. 2023 Jan;149(1):467-481. doi: 10.1007/s00432-022-04408-0. Epub 2022 Oct 19. J Cancer Res Clin Oncol. 2023. PMID: 36260159 Free PMC article. Review.
In chromosomal instable tumors, receptor tyrosine kinases (RKTs) (e.g., EGFR, FGFR2, HER2, and MET) are frequently overexpressed. Gastric cancers such as microsatellite instable and EBV-positive types often express immune checkpoint molecules, such as PD-L1 and VISTA. ...
In chromosomal instable tumors, receptor tyrosine kinases (RKTs) (e.g., EGFR, FGFR2, HER2, and MET) are frequently overexpressed. Gas …
Mapping the genomic diaspora of gastric cancer.
Yeoh KG, Tan P. Yeoh KG, et al. Nat Rev Cancer. 2022 Feb;22(2):71-84. doi: 10.1038/s41568-021-00412-7. Epub 2021 Oct 26. Nat Rev Cancer. 2022. PMID: 34702982 Review.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in genes such as ERBB2, FGFR2, TP53 and ARID1A as well as multiple molecular subtypes. However, clinical efforts targeting these alterations have produced variable results, hampered by …
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in genes such as ERBB2, FGFR2, TP53 and ARID …
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Wainberg ZA, et al. Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14. Lancet Oncol. 2022. PMID: 36244398 Clinical Trial.
Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.
Ma L, Li Y, Luo R, Wang Y, Cao J, Fu W, Qian B, Zheng L, Tang L, Lv X, Zheng L, Liang G, Chen L. Ma L, et al. J Med Chem. 2023 Jun 8;66(11):7438-7453. doi: 10.1021/acs.jmedchem.3c00150. Epub 2023 May 23. J Med Chem. 2023. PMID: 37220310
LC-MB12 preferentially internalizes and degrades membrane-bound FGFR2 among the four FGFR isoforms; this may promote greater clinical benefits. ...Furthermore, LC-MB12 is orally bioavailable and shows significant antitumor effects in FGFR2-dependent gastric cancer i …
LC-MB12 preferentially internalizes and degrades membrane-bound FGFR2 among the four FGFR isoforms; this may promote greater clinical …
Oncogenic structural aberration landscape in gastric cancer genomes.
Saito-Adachi M, Hama N, Totoki Y, Nakamura H, Arai Y, Hosoda F, Rokutan H, Yachida S, Kato M, Fukagawa A, Shibata T. Saito-Adachi M, et al. Nat Commun. 2023 Jun 22;14(1):3688. doi: 10.1038/s41467-023-39263-1. Nat Commun. 2023. PMID: 37349325 Free PMC article.
SV hotspots frequently constitute complexly clustered SVs involved in driver gene amplification, such as ERBB2, CCNE1, and FGFR2. Further deconstruction of the locally clustered SVs uncovers amplicon-generating profiles characterized by super-large SVs and intensive segmen …
SV hotspots frequently constitute complexly clustered SVs involved in driver gene amplification, such as ERBB2, CCNE1, and FGFR2. Fur …
Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
Minashi K, Yamada T, Hosaka H, Amagai K, Shimizu Y, Kiyozaki H, Sato M, Soeda A, Endo S, Ishida H, Kamoshida T, Sakai Y, Shitara K. Minashi K, et al. Jpn J Clin Oncol. 2021 Oct 5;51(10):1523-1533. doi: 10.1093/jjco/hyab104. Jpn J Clin Oncol. 2021. PMID: 34258618 Free PMC article.

In 151 evaluable cases with FGFR2 immunohistochemistry scores of 1-4, FGFR2 copy number expressed as fluorescence in situ hybridization signals were detected as <4, 4 < 10 and 10 copies for 123, 16 and 12 cases, respectively. FGFR2 copy number showed an

…
In 151 evaluable cases with FGFR2 immunohistochemistry scores of 1-4, FGFR2 copy number expressed as fluorescence in situ hybr …
FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort.
Schrumpf T, Behrens HM, Haag J, Krüger S, Röcken C. Schrumpf T, et al. PLoS One. 2022 Feb 15;17(2):e0264011. doi: 10.1371/journal.pone.0264011. eCollection 2022. PLoS One. 2022. PMID: 35167603 Free PMC article.
GCs with moderate and strong FGFR2 expression were studied for Fgfr2 amplification using chromogenic in situ hybridization (CISH). ...FGFR2 expression was associated with a lower tumor grade and intestinal phenotype (p0.0001). ...
GCs with moderate and strong FGFR2 expression were studied for Fgfr2 amplification using chromogenic in situ hybridization (CI …
FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies.
Katoh M. Katoh M. J Invest Dermatol. 2009 Aug;129(8):1861-7. doi: 10.1038/jid.2009.97. Epub 2009 Apr 23. J Invest Dermatol. 2009. PMID: 19387476 Free article. Review.
Fibroblast growth factor receptor (FGFR)2 is regulated on the basis of the balance of FGFs, heparan-sulfate proteoglycans, FGFR2 isoforms, endogenous inhibitors, and microRNAs. FGFR2 signals cross-talk with hedgehog, bone morphogenetic protein, and other regulatory …
Fibroblast growth factor receptor (FGFR)2 is regulated on the basis of the balance of FGFs, heparan-sulfate proteoglycans, FGFR2 isof …
The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
Lee MS, Kaseb AO, Pant S. Lee MS, et al. Clin Cancer Res. 2023 Sep 1;29(17):3267-3274. doi: 10.1158/1078-0432.CCR-22-3626. Clin Cancer Res. 2023. PMID: 37092904 Review.
These applications have proven instructive in patients with HER2-amplified gastric and esophageal cancers and in patients with FGFR2 fusion cholangiocarcinomas. In this review, we summarize data supporting the role of ctDNA as a novel predictive and prognostic biomarker an …
These applications have proven instructive in patients with HER2-amplified gastric and esophageal cancers and in patients with FGFR2 …
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H. Sootome H, et al. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24. Cancer Res. 2020. PMID: 32973082
The frequency of appearance of drug-resistant clones was lower with futibatinib than a reversible ATP-competitive FGFR inhibitor, and futibatinib inhibited several drug-resistant FGFR2 mutants, including the FGFR2 V565I/L gatekeeper mutants, with greater potency tha …
The frequency of appearance of drug-resistant clones was lower with futibatinib than a reversible ATP-competitive FGFR inhibitor, and futiba …
217 results